Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01894152 · ClinicalTrials.gov registry record
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 2,002
- Enrollment target
NCT01894152 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,002 participants.
The verdict
NCT01894152 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 2,002 participants
- Enrollment target
Study Summary
Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on August 10th, 2011. This prospective, observational, open-label, multi-center, single-arm, post-approval study is designed to evaluate the continued safety and effectiveness of the XIENCE PRIME EECSS in a cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in real-world settings in China. This study has no primary outcome measure. All observations are of equal weight.
Interventions
- DEVICE XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,002 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-10-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01894152
The ClinicalTrials.gov registry entry for NCT01894152 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,002 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) is the first listed.
NCT01894152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01894152 about?
NCT01894152 is a clinical study titled "XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study". Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on August 10th, 2011. This prospective, observational, open-label, multi-center, single-arm, post-approval ...
What is the current status of trial NCT01894152?
This trial is currently completed. The enrollment target is 2,002 participants. The study started on 2013-07. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT01894152?
The interventions under investigation include: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) (DEVICE).
Who is sponsoring clinical trial NCT01894152?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.